Description
NIACIN, USP | 100.6% purity
(nicotinic acid)
unaltered, immediate-release powder (“flush” niacin)
– Professionally manufactured in the U.S.A. by chemical synthesis
– GMO free; Non-BSE/TSE (not from animal or plant source); cGMP-compliant
– No elemental impurities, allergens, heavy metals, sulfates, chloride, pesticides, melamine, nitrosamine, antibiotics, aflatoxins, BPA, CMR substances, parabens, phthalates, preservatives, residual solvents, or other chemicals
– Officially tested and certified to meet USP–NF (United States Pharmacopeia – National Formulary) specifications
* * *
TRYPTOPHAN, USP | 100.3% purity
(L-tryptophan)
crystalline powder
– Professionally manufactured in the U.S.A. by chemical synthesis (fermentation)
– GMO free; Non-BSE/TSE (not from animal source); cGMP-compliant
– No elemental impurities, allergens, heavy metals, sulfates, chloride, pesticides, melamine, nitrosamine, antibiotics, aflatoxins, BPA, CMR substances, parabens, phthalates, preservatives, residual solvents, or other chemicals
– Officially tested and certified to meet USP–NF (United States Pharmacopeia – National Formulary) specifications
– – – – – – – – – – – – – – – – – – –
When niacin/NAD⁺ grows insufficient, two things happen that both work against the free-tryptophan pool available for serotonin→melatonin:
1. Supply side (delivery of free Trp falls).
Unaddressed continued lack but growing demand for nicotinic acid damages the gut and impairs exocrine pancreas (smaller gland, lower trypsin/chymotrypsin/amylase stores and secretion). That reduces protein digestion and amino-acid absorption, so less free Trp appears in plasma from a given meal.
2. Demand side (diversion of Trp rises).
A low NAD⁺ state disinhibits the de novo pathway (quinolinate → NaMN) and, with any inflammation or stress, IDO/TDO push Trp down the kynurenine pathway. Net effect: a larger fraction of a smaller Trp pool is consumed to rebuild NAD⁺, leaving less for serotonin and melatonin.
This process continuing to ensue unchecked defines aging and disease.
* * *
Whether for targeted recovery or peak performance optimization, InfinaLife embodies the mission of our 501(c)(3)-registered nonprofit public charity research organization, HOM3OSTASIS by 1 Party At A Time (EIN: 82‑1690789) anchored through Dmitry Kats PhD, MPH: to pioneer the advancement of rigorously calibrated scientific knowledge into public‑health impact.
Reviews
There are no reviews yet.